With the recent improvements in the stability of RNA, nanoparticle technology, and targeted delivery, RNAi-based therapy is expected to arise as a promising approach to target the EGFR/PI3K/AKT/mTOR signaling specifically and effectively in HCC in vivo. This evidence concerns the gene EGFR and hepatocellular carcinoma.